The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. "With skyrocketing prescription drug price increases presenting hospitals, health systems and patients with remarkable challenges, the 340B program is as critical as ever in helping provide access to health care services for vulnerable patients and communities,” said AHA Executive Vice President Tom Nickels. “The 340B ceiling price and civil monetary penalties rule were intended to shine needed light on drug manufacturer price increases and hold drug manufacturers accountable for price overcharging. These reasons are why we continue to be disappointed in the delays – including five times since the beginning of last year alone – of the final rule and in the short shrift given to the review of the latest public comments. The irony is not lost on us that drug manufacturers continue to lobby for increased reporting for hospitals and others while refusing any transparency on their part."

Related News Articles

The AHA and American Association for Physician Leadership today released Leadership Evolve, a collection of digital resources on dyad leadership and workforce…
Insights and Analysis
Learn how an Oregon association collaborated with community stakeholders to produce an evidence-based toolkit to prevent workplace violence.
Chairperson's File
There is no doubt that enhanced convenience and customer service is where health care is headed.
The Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology today released an updated Trusted Exchange…
The AHA today voiced support for the Recovering Excessive Funds for Unused and Needless Drugs Act (S. 551), legislation that would incentivize manufacturers to…
The Federal Trade Commission will hold a public workshop June 18 in Washington, D.C., to assess the impact of certificates of public advantage on health care…